Bench International > blog new  > Bench International Sets Stage for Chase Pharmaceuticals’ Sale to Allergan

Bench International Sets Stage for Chase Pharmaceuticals’ Sale to Allergan

By DeeDee DeMan – Bench International is honored to have been entrusted by the investors committed to Chase Pharmaceuticals to find and deliver the Pharma industry’s marquee leaders who have brought Chase to the forefront, from a little known company to a company with a high potential block-buster drug for Alzheimer’s Disease.

Bench was retained by the board of directors of Chase Pharmaceuticals 2 years ago to recruit a Pharma industry drug development leader to join its board and subsequently retained to recruit the company’s CEO.  Chase was recently acquired by Allergan PLC for a $125 million up-front payment in a deal that could top $1 billion.

Read the original article at PR Newswire